Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trinean to Enter into Global Supply Agreement with QIAGEN

Published: Tuesday, January 21, 2014
Last Updated: Tuesday, January 21, 2014
Bookmark and Share
Trinean to manufacture and supply the QIAxpert - a micro-volume spectrometer for DNA and RNA quantitation and quality analysis.

Trinean has announced that it has entered into a manufacturing and supply agreement with QIAGEN for the production of the QIAxpert, a micro-volume spectrometer for DNA and RNA quantitation and quality analysis.

This platform is a UV/VIS spectrophotometer which contains tailor-made solution for QIAGEN customers using QIAGEN’s DNA and RNA sample technologies and devices for quality control applications.

“We are very pleased with this agreement between QIAGEN and Trinean,” comments Philippe Stas, CEO of Trinean. "Adoption of our technology by QIAGEN, the market leader in DNA and RNA sample technologies, is an important new step in the global validation of our innovative take on UV-VIS spectroscopy.”

“Quality control (QC) is becoming increasingly important in nucleic acid based testing as novel detection technologies become more and more sensitive.” Dietrich Hauffe, Senior VP ,Head of Business Area Life Sciences at QIAGEN adds.

“The QIAxpert system provides a unique combination of accurate quantification and the capability to discriminate between molecules of interest. The system allows us to match high-performance sample technologies, in particular isolation, extraction and purification with high-speed spectrophotometry for confirmatory purposes. It will contribute to superior data output across all analytical workflows using DNA or RNA, from PCR to next generation sequencing. QIAxpert can also allow our customers to make better informed decisions with regards to usage of samples in subsequent downstream processes, reducing the risk of repeat experiments. These benefits can result in significant time and cost savings while at the same time increasing the quality of data output with significant advantages in research, applied and clinical markets.”

“This agreement significantly boosts the market reach of our spectrometry technology”, said Yvan Sergeant, VP Commercial Operations of Trinean. “It combines microfluidics with innovative spectral content profiling software for accurate quantitation of biological samples and further illustrates the importance of our ability to have a sound purity check of biological samples prior to any genetic test.”

The QIAxpert is a customized version of the Xpose reader, launched by Trinean early 2013. The platform redefines manual UV/VIS quantification into a convenient, high speed solution. The drop and read approach avoids time-consuming sample loading and cleaning steps thereby minimizing the hands-on time on the reader.

The full-color touch screen gives single touch access to advanced analytical software, including dye-free specific quantification of DNA, RNA or protein in samples containing interfering components, using Trinean’s proprietary algorithms for UV/VIS spectral deconvolution.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trinean to be Awarded ISO 9001:2008 Certification
Certification awarded for Trinean’s Quality Management System.
Tuesday, February 03, 2015
Trinean to Appoint New Board Member
Company announced that it appointed Mr Chris van Ingen as independent board member.
Friday, May 02, 2014
Trinean Signs a Global Agreement with Bayer CropScience
Bayer will use Trinean’s technology for biomolecule QC using spectral content profiling.
Wednesday, June 12, 2013
Trinean Secures 1 Million Euro Financing
Capricorn Health-tech Fund to join the investor base.
Wednesday, May 29, 2013
Trinean Appoints New CEO and Secures 2.7 Million Euro Financing
Appointment of Philippe Stas as Company’s new CEO.
Monday, April 30, 2012
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Battery Component Found to Harm Key Soil Microorganism
The material at the heart of the lithium ion batteries that power electric vehicles, laptop computers and smartphones has been shown to impair a key soil bacterium, according to new research.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!